ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 71 for:    Taste Disorders | NIH

Development of Novel, Biophysically Designed Fluids for Swallowing Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03131869
Recruitment Status : Recruiting
First Posted : April 27, 2017
Last Update Posted : April 28, 2017
Sponsor:
Collaborator:
National Institute of Nursing Research (NINR)
Information provided by (Responsible Party):
Swallow Solutions

Brief Summary:
People suffering from swallowing disorders (dysphagia) have a hard time swallowing liquids that are too thin (like water or coffee) or too thick, correctly. They can have health problems, such as chest infections and malnutrition because when they try to drink, some of the liquid "goes down the wrong pipe" and into the lungs. To help people with dysphagia, Swallow Solutions is developing thickened liquids that have added nutrition, taste good, and quench thirst, but are still easy and safe to swallow.

Condition or disease Intervention/treatment
Deglutition Disorders Other: Thickened Beverages Nectar Other: Thickened Beverage Honey

Detailed Description:

A. Background Dysphagia, a devastating swallowing disorder affecting more than 18M adults and millions more children in the U.S. [1,2], is associated with increased mortality and morbidity, including malnutrition, dehydration, pulmonary complications, and reduced quality of life [3,4]. Dysphagia often causes thin liquids (e.g., water, coffee) to be aspirated or misdirected into the pulmonary—rather than to the digestive—system during swallowing, significantly increasing the risk of aspiration pneumonia [5,6]. Radiographic methods used in >80% of U.S. hospitals to diagnose dysphagia involve standardized fluids with specific rheological characteristics (e.g., apparent viscosity, flow properties) [7]. Thickened beverages are the most commonly recommended intervention after dysphagia diagnosis [8]. Perplexingly, currently available dietary beverages differ from the rheological characteristics of standardized diagnostic fluids, causing a critical disconnect between diagnosis and treatment [9]. A rheologic study of commercially available thickened beverages and diagnostic fluids found that some commercial nectar products, while approaching the target apparent viscosity (n ) for the diagnostic standard (Varibar® Nectar, n 30=300 cP), differed in other rheological parameters such as flow index (n), consistency (K), and yield stress. o commercial thin-honey consistency products matched the diagnostic standard for any of these rheological parameters. This disconnect frequently causes the bolus to flow toward the airway, increasing the risk of negative health sequelae.

Swallow Solutions, LLC will build on the successful completion of our Phase I project to continue to bridge the gap between clinical need and existing products. Based on insights from our Phase I results, investigators will develop a complete product line (tentatively branded as SwallowSAFE Thickened Beverages) to meet the unique—currently unmet—needs of dysphagic patients. This novel thickened beverage line will provide hydration and nutrition, thus circumventing potentially life-threatening and costly health problems associated with dysphagia. The investigators propose to accomplish the following specific aims.

Specific Aims

Aim 1. Complete a full complement of prototype ready-to-drink, thickened, and nutritionally-enhanced medical liquids that are shelf-stable and appealing, with pre-determined rheological and nutritional properties. T

Aim 2. Demonstrate improved patient safety resulting from novel, biophysically designed thickened beverages (full product line) compared to currently available thickened beverage options.

Aim 3. Develop production for the full SwallowSAFE product line of ready-to-drink, thickened beverages (with and without nutritional enrichment) at 2 target viscosities (nectar and thin-honey) in 1-3 flavors each.

B. Study Design: Clinical Research (Aim 2)

Dysphagic patients (n=200) will swallow prototype beverages (with 10% added barium) and also thickened beverages that are currently on the market (with 10% added barium) during a videofluoroscopic (radiographic) evaluation of swallowing that is part of their standard clinical care. The investigators will use established, quantified, objective safety measures of a) airway invasion (Penetration/Aspiration Scale) [13,14] and b) oropharyngeal residue [15]. Potential subjects will be adults (age >55 years) with suspected dysphagia based on referral for the diagnostic evaluation. The study will include patients with a variety of medical etiologies to allow for greater generalizability of results. Each consenting subject will complete a videofluoroscopic swallowing assessment lasting ~45 min per standard clinical care. Data will be collected from 200 subjects from two large acute-care hospitals.


Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of Novel, Biophysically Designed Fluids for Swallowing Disorders
Actual Study Start Date : February 22, 2017
Estimated Primary Completion Date : July 1, 2018
Estimated Study Completion Date : July 1, 2018

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: Thickened Beverages Nectar
    Thickened beverages in nectar consistency
  • Other: Thickened Beverage Honey
    Thickened beverages in honey consistency


Primary Outcome Measures :
  1. Penetration - Aspiration Scale [ Time Frame: immediately while swallowing ]
    presence of aspiration/penetration of the laryngeal vestibule


Secondary Outcome Measures :
  1. Post-swallow Residue [ Time Frame: immediately while swallowing ]
    quantification of oropharyngeal residue



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Potential subjects will be adults with suspected dysphagia based on referral for a diagnostic videofluoroscopic swallowing evaluation. Only subjects who can consent for themselves will be enrolled in the study. The consent will take place before the swallow study begins. The study will include patients with a variety of medical etiologies to allow for greater generalizability of results. Pregnant women will be excluded from this protocol. Per standard clinical care (as all subjects will be completing the radiologic procedure regardless of participation in the study), pregnancy test will not be required.
Criteria

Inclusion Criteria:

  • 55 years of age or older
  • physician approval of medical stability
  • aspiration or penetration of the laryngeal vestibule (score of 3 or higher on the Penetration/Aspiration Scale) or post-swallow residue in the oropharynx as instrumentally documented by a Speech-Language Pathologist (SLP) during a standard videofluoroscopic oropharyngeal swallow study
  • capacity to provide informed consent.

Exclusion Criteria:

  • poorly controlled psychosis (3 or more related hospitalizations in one year
  • refractory alcoholism (on AWD precautions)
  • allergy to barium (used in radiographic swallowing assessment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03131869


Contacts
Contact: Jackie Hind, MS 608-238-6678 jahind@swallowsolutions.com

Locations
United States, Wisconsin
Meriter Hospital Recruiting
Madison, Wisconsin, United States, 53715
Contact: Sharon Bair, MS    608-417-6000    sharon.bair@unitypoint.org   
Marshfield Clinic Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Lisa Bast, MS    715-387-5511    bast.lisa@marshfieldclinic.org   
Sponsors and Collaborators
Swallow Solutions
National Institute of Nursing Research (NINR)
Investigators
Principal Investigator: Eric Horler, MBA Swallow Solutions
Principal Investigator: JoAnne Robbins, PhD Swallow Solutions

Responsible Party: Swallow Solutions
ClinicalTrials.gov Identifier: NCT03131869     History of Changes
Other Study ID Numbers: 2R44NR015193-02 ( U.S. NIH Grant/Contract )
2R44NR015193-02 ( U.S. NIH Grant/Contract )
First Posted: April 27, 2017    Key Record Dates
Last Update Posted: April 28, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disease
Deglutition Disorders
Pathologic Processes
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Pharyngeal Diseases
Otorhinolaryngologic Diseases